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A B S T R A C T
Background
Cesarean delivery is one of the most common surgical procedures performed by obstetricians. Infectious morbidity after cesarean
delivery can have a tremendous impact on the postpartum woman’s return to normal function and her ability to care for her baby.
Despite the widespread use of prophylactic antibiotics, postoperative infectious morbidity still complicates cesarean deliveries.
Objectives
To determine if cleansing the vagina with an antiseptic solution before a cesarean delivery decreases the risk of maternal infectious
morbidities, including endometritis and wound complications.
Search methods
We searched the Cochrane Pregnancy and Childbirth Group’s Trials Register (21 July 2014).
Selection criteria
We included randomized and quasi-randomized trials assessing the impact of vaginal cleansing immediately before cesarean delivery
with any type of antiseptic solution versus a placebo solution/standard of care on post-cesarean infectious morbidity.
Data collection and analysis
We independently assessed eligibility and quality of the studies.
Main results
Five trials randomizing 1946 women (1766 analyzed) evaluated the effects of vaginal cleansing (all with povidone-iodine) on post-
cesarean infectious morbidity. The risk of bias was generally low, with the quality of most of the studies being high. Vaginal preparation
immediately before cesarean delivery significantly reduced the incidence of post-cesarean endometritis from 7.2% in control groups to
3.6% in vaginal cleansing groups (average risk ratio (RR) 0.39, 95% confidence interval (CI) 0.16 to 0.97, five trials, 1766 women). The
risk reduction was particularly strong for women with ruptured membranes (1.4% in the vaginal cleansing group versus 15.4% in the
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control group; RR 0.13, 95% CI 0.02 to 0.66, two trials, 148 women). No other outcomes realized statistically significant differences
between the vaginal cleansing and control groups. No adverse effects were reported with the povidone-iodine vaginal cleansing.
The quality of the evidence using GRADE was low for post-cesarean endometritis, moderate for postoperative fever, and low for wound
infection.
Authors’ conclusions
Vaginal preparation with povidone-iodine solution immediately before cesarean delivery reduces the risk of postoperative endometritis.
This benefit is particularly realized for womenundergoing cesarean delivery with rupturedmembranes. As a simple, generally inexpensive
intervention, providers should consider implementing preoperative vaginal cleansing with povidone-iodine before performing cesarean
deliveries.
P L A I N L A N G U A G E S U M M A R Y
Vaginal cleansing before cesarean delivery to reduce post-cesarean infections
Cesarean deliveries are very common today, with almost one in three babies born by cesarean in some countries. Antibiotics are routinely
given before or during the surgery to reduce the risk of infections, but some women still suffer from these complications. Between
one in four and one in 10 women develop an infection of the uterus (endometritis) or a problem with their skin incision, respectively.
These complications slow recovery from the surgery and may affect the mother’s ability to take care of her baby. Other interventions
are needed to further reduce the risk of infections of the uterus and wound problems after cesarean delivery.
This review found that cleansing the vagina with an antiseptic solution immediately before the cesarean delivery reduced the risk of
post-cesarean infection of the uterus (womb) (low quality of evidence). The benefit was greater if the woman’s water had already broken
(the membranes had ruptured). This review did not find that vaginal cleansing reduced the number of women experiencing fever or
wound complications after cesarean delivery. The antiseptic was povidone-iodine, and no adverse events such as allergy or irritation
were noted in any of the five randomized trials, reporting on 1766 women, from vaginal preparation solution.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Vaginal preparation versus control for preventing postoperative infections
Population: Pregnant women who received a cesarean delivery
Settings: A hospital in Iran and hospitals in USA
Intervention: Vaginal preparation with povidone-iodine solution versus control (saline vaginal wash; no vaginal cleansing)
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Control Vaginal preparation ver-
sus control
Post-cesarean
endometritis
Study population RR 0.39
(0.16 to 0.97)
1766
(5 studies)
⊕⊕©©
low1,2
72 per 1000 28 per 1000
(12 to 70)
Moderate
75 per 1000 29 per 1000
(12 to 73)
Postoperative fever Study population RR 0.92
(0.71 to 1.18)
1606
(4 studies)
⊕⊕⊕©
moderate2,3
134 per 1000 123 per 1000
(95 to 158)
Moderate
117 per 1000 108 per 1000
(83 to 138)
Wound infection Study population RR 0.99
(0.57 to 1.7)
1336
(4 studies)
⊕⊕©©
low2,4,5
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37 per 1000 37 per 1000
(21 to 63)
Moderate
41 per 1000 41 per 1000
(23 to 70)
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio;
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 Statistical heterogeneity (I2 >60%).
2 Optimal information size not met.
3 Confidence interval crossing the line of no effect.
4 Half of the studies contributing data had design limitations.
5 Wide confidence interval crossing the line of no effect.
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B A C K G R O U N D
Cesarean sections currently account for approximately one-third
of the babies born in the United States. Cesarean section deliveries
are often complicated by infections occurring after the surgery.
Description of the condition
Endometritis, an infection of the uterus in the postpartum period,
can complicate the postoperative course of a cesarean delivery 6%
to 27% of the time (Guzman 2002; Hofmeyr 2002). This com-
plication, up to 10 times more frequent after a cesarean delivery
than after vaginal delivery, can lead to serious complications of
bacterial infection in the blood (10% to 20%), peritonitis (gen-
eral infection in the abdominal cavity), intra-abdominal abscess
(cavity filled with infected material), and sepsis (French 2004;
Yokoe 2001). Additionally, cesarean deliveries are frequently com-
plicated by maternal fever and wound complications including
seroma (fluid collection under the skin), hematoma (blood clots
under the skin), infection, and separation. These morbidities can
lead to significant delay in a return to normal function.
Fevers and infections after cesarean deliveries are associated with
the length of rupturedmembranes, length of labor, and number of
vaginal examinations (Disgupta 1988; Yonekura 1985). Post-ce-
sarean endometritis and infectiousmorbidity are the result often of
the presence of bacteria in the vagina and cervix that move higher
in the genital tract to infect the uterus (Martens 1991). These
bacteria have been shown to be responsible for failure of antibiotic
prophylaxis during cesarean deliveries (Watts 1991). Additionally,
some antibiotics do not consistently eradicate some bacteria (such
as enterococcus) and the vagina has been shown to become colo-
nized with antibiotic-resistant bacteria after preoperative surgical
antibiotic prophylaxis (Gibbs 1982; Graham 1993; Stiver 1984).
Currently, it is standard care to give antibiotics to women receiving
a cesarean delivery, but the rate of post-cesarean infections remains
a problem.
Description of the intervention
Previous studies have evaluated whether vaginal cleansing before a
cesarean delivery with various solutions can reduce the incidence
of febrile morbidity (endometritis and wound infections). Povi-
done iodine, chlorhexidine, and vaginal metronidazole have been
reported with varying results. Older data comparing iodine with
chlorhexidine before hysterectomy showed lower morbidity in the
iodine group, with improved activity against anaerobic pathogens
(Duignan 1975; Haeri 1984). Currently, it is not standard care in
the United States to prepare the vagina with an antiseptic solu-
tion before cesarean delivery. Vaginal cleansing solutions such as
chlorhexidine and povidone iodine have very few side effects in
general, with low rates of noted allergies or irritation symptoms.
How the intervention might work
By cleansing the vagina of bacteria before the cesarean delivery
occurs, theremay be less of a bacterial load in the vagina that might
cause infectious morbidity postoperatively. As ascending infection
is thought to be a major etiology of postoperative endometritis,
this could logically reduce that risk.
Why it is important to do this review
Cesarean delivery is increasing, particularly in the developed
world. Postoperative infectious morbidity after cesarean delivery
impacts the woman’s return to normal function and potentially
her bonding with the newborn. It can also cause major medical
problems and sequelae. Finding an easy, inexpensive method to
reduce this risk could have major public health impact in both
developed and developing countries.
O B J E C T I V E S
Our objective was to determine if cleansing the vagina with an
antiseptic solution before a cesarean delivery decreases the risk of
maternal morbidities, including endometritis and wound compli-
cations. We also assessed the side effects of vaginal cleansing solu-
tions to determine adverse events associated with the intervention.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomized and quasi-randomized studies.
Types of participants
Pregnant women who received a cesarean delivery.
Types of interventions
Any method of vaginal cleansing (including douches, wipes,
sponges, etc.) with any type of antiseptic solution (povidone io-
dine, chlorhexidine, etc.) versus a placebo solution/standard care
(no vaginal preparation).
We included only studieswhere vaginal preparationwas performed
no more than one hour before surgery. This review addressed the
use of preoperative vaginal cleansing after the decision to perform
a cesarean had been made. This review did not address the use of
vaginal preparation during labor. Thus, we excluded trials utilizing
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vaginal cleansing solutions during labor. We also excluded studies
where prophylactic surgical antibiotics were explicitly not used.
Surgical prophylaxis with intravenous antibiotics before or dur-
ing cesarean deliveries has been clearly demonstrated as beneficial
in reducing postoperative infectious morbidities. Thus, it is the
standard of care. Inclusion of trials not utilizing general surgical
antibiotic prophylaxis would not represent the current standard of
care and the results would not be translatable into current practice.
Types of outcome measures
Primary outcomes
Postpartum endometritis: defined as a clinical diagnosis, usually
involving fever, uterine fundal tenderness, or purulent lochia re-
quiring antibiotic therapy.
Secondary outcomes
• Postoperative wound infection: defined as erythema,
tenderness, purulent drainage from the incision site, with or
without fever, requiring antibiotic therapy.
• Postoperative fever: defined as greater than 38 degrees C or
100.4 degrees F.
• Postoperative wound seroma or hematoma: defined as
collection of serous fluid or blood/clot in the subcutaneous area
of the incision.
• Composite wound complications: defined as the presence
of any one of the following: wound infection, seroma,
hematoma, separation.
• Composite wound complications or endometritis.
• Side effects of vaginal preparation (allergy, irritation). As
these solutions are applied gently and not absorbed, there should
be no adverse fetal/neonatal effects. We did not anticipate or find
mention of adverse neonatal effects from the vaginal cleansing.
Search methods for identification of studies
The followingmethods section of this review is based on a standard
template used by the Cochrane Pregnancy and Childbirth Group.
Electronic searches
We contacted the Trials Search Co-ordinator to search the
Cochrane Pregnancy and Childbirth Group’s Trials Register (21
July 2014).
The Cochrane Pregnancy and Childbirth Group’s Trials Register
is maintained by the Trials Search Co-ordinator and contains trials
identified from:
1. monthly searches of the Cochrane Central Register of
Controlled Trials (CENTRAL);
2. weekly searches of MEDLINE;
3. weekly searches of Embase;
4. handsearches of 30 journals and the proceedings of major
conferences;
5. weekly current awareness alerts for a further 44 journals
plus monthly BioMed Central email alerts.
Details of the search strategies for CENTRAL, MEDLINE and
Embase, the list of handsearched journals and conference pro-
ceedings, and the list of journals reviewed via the current aware-
ness service can be found in the ‘Specialized Register’ section
within the editorial information about the Cochrane Pregnancy
and Childbirth Group.
Trials identified through the searching activities described above
are each assigned to a review topic (or topics). The Trials Search
Co-ordinator searches the register for each review using the topic
list rather than keywords.
We did not apply any language restrictions.
Data collection and analysis
For the methods used when assessing the trials identified in the
previous version of this review, see Haas 2013.
For this update, no new studies were identified. We will use the
methods outlined in Appendix 2 for new trials identified at the
next update.
We used the following updated methods to assess the risk of bias
and assess the quality of already included studies using theGRADE
approach. The followingmethods section of this review is based on
a standard template used by the Cochrane Pregnancy and Child-
birth Group.
Selection of studies
All three review authors independently assessed for inclusion all
the potential studies identified as a result of the search strategy.
We resolved any disagreement through discussion.
Data extraction and management
We designed a form to extract data. For eligible studies, all three
review authors extracted the data using the agreed form. We re-
solved discrepancies through discussion. We entered data into Re-
view Manager software (RevMan 2011).
When information regarding any of the above was unclear, we
attempted to contact authors of the original reports to provide
further details.
Assessment of risk of bias in included studies
Three review authors independently assessed risk of bias for each
study using the criteria outlined in the Cochrane Handbook for
Systematic Reviews of Interventions (Higgins 2011). We resolved
any disagreement by discussion.
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(1) Random sequence generation (checking for possible
selection bias)
We described for each included study the method used to generate
the allocation sequence in sufficient detail to allow an assessment
of whether it should produce comparable groups.
We assessed the method as:
• low risk of bias (any truly random process, e.g. random
number table; computer random number generator);
• high risk of bias (any non-random process, e.g. odd or even
date of birth; hospital or clinic record number);
• unclear risk of bias.
(2) Allocation concealment (checking for possible selection
bias)
We described for each included study the method used to con-
ceal allocation to interventions prior to assignment and assessed
whether intervention allocation could have been foreseen in ad-
vance of, or during recruitment, or changed after assignment.
We assessed the methods as:
• low risk of bias (e.g. telephone or central randomization;
consecutively numbered sealed opaque envelopes);
• high risk of bias (open random allocation; unsealed or non-
opaque envelopes, alternation; date of birth);
• unclear risk of bias.
(3.1) Blinding of participants and personnel (checking for
possible performance bias)
We described for each included study the methods used, if any, to
blind study participants and personnel from knowledge of which
intervention a participant received. We considered that studies
were at low risk of bias if they were blinded, or if we judged that
the lack of blinding would be unlikely to affect results.We assessed
blinding separately for different outcomes or classes of outcomes.
We assessed the methods as:
• low, high or unclear risk of bias for participants;
• low, high or unclear risk of bias for personnel.
(3.2) Blinding of outcome assessment (checking for possible
detection bias)
We described for each included study the methods used, if any, to
blind outcome assessors from knowledge of which intervention a
participant received. We assessed blinding separately for different
outcomes or classes of outcomes.
We assessed methods used to blind outcome assessment as:
• low, high or unclear risk of bias.
(4) Incomplete outcome data (checking for possible attrition
bias due to the amount, nature and handling of incomplete
outcome data)
We described for each included study, and for each outcome or
class of outcomes, the completeness of data including attrition
and exclusions from the analysis. We stated whether attrition and
exclusions were reported and the numbers included in the analysis
at each stage (compared with the total number of randomized
participants), reasons for attrition or exclusion where reported,
and whether missing data were balanced across groups or were
related to outcomes. Where sufficient information was reported,
or could be supplied by the trial authors, we planned to re-include
missing data in the analyses.
We assessed methods as:
• low risk of bias (e.g. no missing outcome data; missing
outcome data balanced across groups);
• high risk of bias (e.g. numbers (> 20%) or reasons for
missing data imbalanced across groups; ‘as treated’ analysis done
with substantial departure of intervention received from that
assigned at randomization);
• unclear risk of bias.
(5) Selective reporting (checking for reporting bias)
We described for each included study how we investigated the
possibility of selective outcome reporting bias and what we found.
We assessed the methods as:
• low risk of bias (where it is clear that all of the study’s pre-
specified outcomes and all expected outcomes of interest to the
review have been reported);
• high risk of bias (where not all the study’s pre-specified
outcomes have been reported; one or more reported primary
outcomes were not pre-specified; outcomes of interest are
reported incompletely and so cannot be used; study fails to
include results of a key outcome that would have been expected
to have been reported);
• unclear risk of bias.
(6) Other bias (checking for bias due to problems not
covered by (1) to (5) above)
We described for each included study any important concerns we
had about other possible sources of bias.
We assessed whether each study was free of other problems that
could put it at risk of bias:
• low risk of other bias;
• high risk of other bias;
• unclear whether there is risk of other bias.
(7) Overall risk of bias
We made explicit judgements about whether studies were at high
risk of bias, according to the criteria given in the Handbook (
Higgins 2011). With reference to (1) to (6) above, we assessed
the likely magnitude and direction of the bias and whether we
considered it likely to impact on the findings. In future updates, if
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more studies are included, we will explore the impact of the level
of bias through undertaking sensitivity analyses - see Sensitivity
analysis.
For this update, the quality of the evidence was assessed using
the GRADE approach (Schunemann 2009) in order to assess the
quality of the body of evidence relating to the following outcomes
for the main comparisons.
1. Postpartum endometritis.
2. Postoperative wound infection.
3. Postoperative fever.
GRADEprofiler (Grade 2008) was used to import data from Re-
view Manager 5.3 (RevMan 2014) in order to create a ’Summary
of findings’ table. A summary of the intervention effect and amea-
sure of quality for each of the above outcomes was produced us-
ing the GRADE approach. The GRADE approach uses five con-
siderations (study limitations, consistency of effect, imprecision,
indirectness and publication bias) to assess the quality of the body
of evidence for each outcome. The evidence can be downgraded
from ’high quality’ by one level for serious (or by two levels for very
serious) limitations, depending on assessments for risk of bias, in-
directness of evidence, serious inconsistency, imprecision of effect
estimates or potential publication bias.
Measures of treatment effect
Dichotomous data
For dichotomous data, we presented results as summary risk ratio
with 95% confidence intervals.
Continuous data
For continuous data, we planned to use themean difference if out-
comes were measured in the same way between trials. We planned
to use the standardized mean difference to combine trials that
measured the same outcome, but used different methods.
Unit of analysis issues
Cluster-randomized trials
There were no cluster-randomized trials. If in future updates some
are identified, we will include cluster-randomized trials in the
analyses along with individually-randomized trials. We will adjust
their sample sizes using the methods described in the Handbook
(Higgins 2011) using an estimate of the intracluster correlation co-
efficient (ICC) derived from the trial (if possible), from a similar
trial or from a study of a similar population. If we use ICCs from
other sources, we will report this and conduct sensitivity analyses
to investigate the effect of variation in the ICC. If we identify both
cluster-randomized trials and individually-randomized trials, we
plan to synthesize the relevant information. We will consider it
reasonable to combine the results from both if there is little het-
erogeneity between the study designs and the interaction between
the effect of intervention and the choice of randomization unit is
considered to be unlikely.
We will also acknowledge heterogeneity in the randomization unit
and perform a sensitivity analysis to investigate the effects of the
randomization unit.
Cross-over trials
Cross-over trials are not possible for this intervention and are not
included.
Other unit of analysis issues
We included quasi-randomized trials but noted their increased risk
of bias in this design.
Dealing with missing data
For included studies, we noted levels of attrition. We did not
encounter large levels of attrition. In future updates, if we do
encounter large levels of attrition, we will explore the impact of
including studies with high levels of missing data in the overall
assessment of treatment effect by using sensitivity analysis.
For all outcomes, we carried out analyses, as far as possible, on
an intention-to-treat basis, i.e. we attempted to include all partic-
ipants randomized to each group in the analyses, and all partici-
pants were analyzed in the group to which they were allocated, re-
gardless of whether or not they received the allocated intervention.
The denominator for each outcome in each trial was the number
randomized minus any participants whose outcomes were known
to be missing.
Assessment of heterogeneity
We assessed statistical heterogeneity in each meta-analysis using
the Tau², I² and Chi² statistics. We regarded heterogeneity as sub-
stantial if the I² was greater than 30% and either a Tau² was greater
than zero, or there was a low P value (less than 0.10) in the Chi²
test for heterogeneity.
Assessment of reporting biases
There are only five studies included. If there are 10 or more studies
in the meta-analysis at a future update, we will investigate report-
ing biases (such as publication bias) using funnel plots. We will
assess funnel plot asymmetry visually. If asymmetry is suggested
by a visual assessment, we will perform exploratory analyses to
investigate it.
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Data synthesis
We carried out statistical analysis using the Review Manager soft-
ware (RevMan 2011). We used fixed-effect meta-analysis for com-
bining data where it was reasonable to assume that studies were
estimating the same underlying treatment effect: i.e. where trials
were examining the same intervention, and the trials’ populations
and methods were judged sufficiently similar. If there was clinical
heterogeneity sufficient to expect that the underlying treatment ef-
fects differed between trials, or if substantial statistical heterogene-
ity was detected, we used random-effects meta-analysis to produce
an overall summary, if an average treatment effect across trials was
considered clinically meaningful. The random-effects summary
was treated as the average range of possible treatment effects and
we discussed the clinical implications of treatment effects differing
between trials. If the average treatment effect was not clinically
meaningful, we did not combine trials.
Where we used random-effects analyses, the results are presented
as the average treatment effect with 95% confidence intervals, and
the estimates of Tau² and I².
Subgroup analysis and investigation of heterogeneity
In future updates, if we identify substantial heterogeneity, we will
investigate it using subgroup analyses and sensitivity analyses. We
will consider whether an overall summary is meaningful, and if it
is, use random-effects analysis to produce it.
For this update, we carried out the following subgroup analyses.
1. Women in labor versus women not in labor.
2. Women with ruptured membranes versus women with
intact membranes.
3. Women with chorioamnionitis preoperatively versus
women without chorioamnionitis.
4. Women undergoing emergency cesarean versus those
undergoing unscheduled cesarean versus those undergoing
scheduled cesarean.
5. Women with internal fetal or uterine monitors in place
versus those with only external monitors in place before the
cesarean.
All reported outcomes in the primary analysis were used in the
subgroup analyses.
We assessed subgroup differences by interaction tests available
within RevMan (RevMan 2011). We reported the results of sub-
group analyses quoting the Chi² statistic and P value, and the in-
teraction test I² value.
Sensitivity analysis
We did not perform any sensitivity analyses due to a lack of studies
included within analyses. In future updates, we plan to carry out
sensitivity analyses to explore the effect of trial quality assessed by
concealment of allocation, high attrition rates (> 20%), or both,
with poor quality studies being excluded from the analyses, in
order to assess whether this makes any difference to the overall
result.
R E S U L T S
Description of studies
Results of the search
The original search yielded six reports of four studies. The search
of the Pregnancy andChildbirthGroup’s Trials Register conducted
in August 2012 resulted in three further trial reports. One was the
published report of Haas 2010 and the other two were reports of
one trial Asghania 2011. We obtained full data from the authors.
The 2014 search did not identify any new reports for our consid-
eration.
Included studies
All five studies qualified for inclusion in this review. All five studies
compared preoperative vaginal povidone-iodine solution prepara-
tion with a control group. In one trial (Guzman 2002), the control
group was a saline vaginal wash. The other four trials compared
the vaginal cleansing with no vaginal cleansing (Asghania 2011;
Haas 2010; Reid 2001; Starr 2005).
Excluded studies
No studies were excluded.
Risk of bias in included studies
See ’Risk of bias’ tables for the five included studies in
Characteristics of included studies and Figure 1; and Figure 2, for
summaries of ’Risk of bias’ assessments. Overall, the quality of
these five studies was generally high as defined by Higgins 2008.
Most of the information for the review is derived from studies at
low risk of bias. All the studies reported on the outcome of en-
dometritis, while four reported on postoperative fever and wound
infection. Two studies reported any wound complication and only
one study reported a composite of endometritis or any wound
complication. One trial excluded women with chorioamnionitis
(Starr 2005). Two trials excluded women undergoing emergency
cesarean deliveries (Guzman 2002; Reid 2001).
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Figure 1. Methodological quality graph: review authors’ judgements about each methodological quality
item presented as percentages across all included studies.
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Figure 2. Methodological quality summary: review authors’ judgements about each methodological quality
item for each included study.
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Allocation
Only the Guzman 2002 study was unclear about the randomiza-
tion sequence generation and allocation concealment.The trial,
however, appeared free of any other biases. One study (Asghania
2011) was a quasi-randomized trial with alternate allocation.
Blinding
All five trials blinded outcomes assessors andmost had somemech-
anism for blinding of providers or were unclear about whether
participants were blinded.
Incomplete outcome data
Only the Reid 2001 study was felt to potentially have incomplete
outcome bias. This stems from the post-hoc exclusion of women
with chorioamnionitis.
Selective reporting
One trial (Reid 2001) had a large number of participants excluded
after randomization who had chorioamnionitis (a known risk fac-
tor for postoperative infectious morbidity) because their inclusion
“distorted the absolute rates of fever and infectious morbidity.”
That trial states that when the 68 participants with antepartum
infection were included, the estimates of effect of vaginal prepa-
ration were not meaningfully different. Thus they planned to ex-
clude those participants from reports of outcomes. As this repre-
sented 13.5% of the originally randomized sample, however, there
is a risk that this introduced selective reporting bias into the trial
(Reid 2001). One other trial had a potential selective reporting
bias (Starr 2005). Of 400 participants randomized, 92 (23%) were
excluded after randomization: 33 due to lost envelopes, six for vi-
olations of inclusion criteria, and 53 because their hospital charts
could not be located. Of all the women excluded, 54 were in the
vaginal cleansing group and 38 were in the control group. Only
outcomes for women for whom all data were available were re-
ported. The large number of women excluded also makes this trial
subject to an unclear risk of bias, however as there is no outcome
data for the excluded participants, the potential impact is unclear
(Starr 2005).
Other potential sources of bias
One trial (Haas 2010) was stopped early at a planned safety anal-
ysis due to difficulty recruiting participants. The Asghania 2011
trial excluded women with potential infection before the surgery,
including chorioamnionitis, but this was done before enrollment.
Effects of interventions
See: Summary of findings for the main comparison Vaginal
preparation versus control for preventing postoperative infections
We included five trials involving 1946 randomized women (1766
analyzed). One trial (Guzman 2002) compared vaginal povidone-
iodine with a saline vaginal preparation. The remaining four trials
compared vaginal povidone-iodine with no vaginal cleansing (
Asghania 2011; Haas 2010; Reid 2001; Starr 2005).
Vaginal cleansingwith povidone iodine solution reduces the risk of
post-cesarean endometritis from 7.2% in control groups to 3.6%
in vaginal cleansing groups (risk ratio (RR) 0.53, 95% confidence
interval (CI) 0.35 to 0.79, five trials, 1766 women), fixed-effect
meta-analysis. Because of high heterogeneity (I² = 65% and Tau² =
0.58), we used random-effects analysis to produce an overall sum-
mary for this outcome (average RR 0.39, 95% CI 0.16 to 0.97),
see Analysis 1.1. The substantial heterogeneity indicates that treat-
ment effects vary between studies, so we investigated the factors
affecting treatment effects by the prespecified subgroup analyses
(see below). As all of the trials did not include all subgroups, it
is unclear if the subgroup analyses were able to account for all
of the heterogeneity. However, we considered that the trials were
similar enough clinically that the average treatment effect would
be clinically meaningful. Vaginal cleansing did not lead to a sta-
tistically significant reduction in the outcomes of postoperative
fever (RR 0.92, 95% CI 0.71 to 1.18, four trials, 1606 women,
Analysis 1.2), wound infection (RR 0.99, 95% CI 0.57 to 1.70,
four trials, 1336 women, Analysis 1.3), any wound complication
(RR 0.63, 95% CI 0.37 to 1.07, two trials, 729 women, Analysis
1.4), or the composite of endometritis or wound complication
(RR 0.55, 95% CI 0.26 to 1.15, one trial, 299 women, Analysis
1.5). Because of nearly significant heterogeneity (I² = 27%) for
the outcome of postoperative fever and the issues noted above, we
repeated the analysis with a random-effects model, still demon-
strating no significant difference in the rates of postoperative fever
with the intervention (RR 0.91, 95% CI 0.66 to 1.25).
Subgroup analysis - women in labor versus women not in
labor
Two trials (Haas 2010; Reid 2001) stratified data for women in
labor versus not in labor. Both trials reported on the outcomes
of endometritis and any wound complication. There was not a
statistically significant reduction in either of these outcomes for
women in labor (endometritis RR 0.63, 95% CI 0.18 to 2.25,
two trials, 311 women; any wound complication RR 0.77, 95%
CI 0.36 to 1.61, two trials 314 women), see Analysis 2.1; Analysis
2.4. All confidence intervals for the other outcomes overlapped
1.0 for the single trial reporting the other outcomes for women
in labor (postoperative fever: RR 0.22, 95% CI 0.03 to 1.83,
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one trial, 95 women; wound infection: RR 0.67, 95% CI 0.17
to 2.63, one trial, 95 women; endometritis or wound complica-
tion: RR 0.40, 95% CI 0.14 to 1.18, one trial, 95 women), see
Analysis 2.2; Analysis 2.3; Analysis 2.5. The subgroup analysis for
women who were not in labor before the cesarean delivery failed to
demonstrate any statistically significant differences in outcomes,
although the rate of endometritis in this group was higher after a
vaginal cleansing than in the control group (3.7% in the vaginal
cleansing group versus 2.0% in the control group; RR 1.40, 95%
CI 0.20 to 9.86, two trials, 414 women), see Analysis 2.1. This
result was mainly driven by the Reid 2001 study finding. There
was not a statistically significant effect of vaginal cleansing for the
other outcomes (postoperative fever: RR 0.42, 95% CI 0.04 to
4.58, one trial, 201 women; wound infection: RR 0.67, 95% CI
0.19 to 2.43, one trial, 195 women; any wound complication: RR
0.54, 95% CI 0.25 to 1.16, two trials, 415 women; endometritis
or wound complication: RR 0.85, 95% CI 0.29 to 2.56, one trial,
204 women), see Analysis 2.2; Analysis 2.3; Analysis 2.4; Analysis
2.5.
There was also no evidence of any difference between subgroups
according to the test for subgroup differences performed: Test for
subgroup differences: Chi² = 0.45, df = 1 (P = 0.50), I² = 0%,
Analysis 2.1; Chi² = 0.16, df = 1 (P = 0.69), I² = 0%, Analysis 2.2;
Chi² = 0.00, df = 1 (P = 0.99), I² = 0%, Analysis 2.3; Chi² = 0.41,
df = 1 (P = 0.52), I² = 0%, Analysis 2.4; Chi² = 0.92, df = 1 (P =
0.34), I² = 0%, Analysis 2.5.
Subgroup analysis - women with ruptured membranes versus
women with intact membranes
Two trials (Guzman 2002; Haas 2010) stratified data for women
with ruptured membranes versus women without ruptured mem-
branes. Both trials reported on the outcomes of endometritis and
postoperative fever. There was a statistically significant reduction
in the rate of endometritis for women receiving vaginal prepara-
tion with povidone-iodine solution preoperatively with ruptured
membranes (1.4% in the vaginal cleansing group versus 15.4% in
the control group; RR 0.13, 95% CI 0.02 to 0.66, two trials, 148
women), see Analysis 3.1. There were no statistically significant
differences between the vaginal preparation and control groups in
the other outcomes for women with rupturedmembranes (wound
infection: RR 1.50, 95% CI 0.52 to 4.32, two trials, 148 women;
postoperative fever: RR 0.31, 95% CI 0.04 to 2.64, one trial,
76 women; any wound complication: RR 0.53, 95%CI 0.15 to
1.89, 1 trials, 76 women; endometritis or wound complication:
RR 0.46, 95%CI 0.13 to 1.61, one trial, 76 women), see Analysis
3.3; Analysis 3.2; Analysis 3.4; Analysis 3.5. For women with in-
tact membranes, the rate of postoperative endometritis was not
significantly reduced in the vaginal preparation group (0.6% in
the vaginal cleansing group versus 3.4% in the control group; RR
0.26, 95% CI 0.04 to 1.51, two trials, 312 women), see Analysis
3.1. All of the reported outcomes for women without ruptured
membranes were not statistically significantly different between
the vaginal preparation and control groups (postoperative fever:
RR 0.28, 95% CI 0.03 to 2.69, one trial, 224 women; wound
infection: RR 0.67, 95% CI 0.23 to 1.89, two trials, 312 women;
any wound complication: RR 0.73, 95% CI 0.25 to 2.10, one
trial, 224 women; endometritis or wound complication: RR 0.66,
95% CI 0.26 to 1.72, one trial, 224 women), see Analysis 3.2;
Analysis 3.3; Analysis 3.4; Analysis 3.5.
There was also no evidence of any difference between subgroups
according to the test for subgroup differences performed: Test for
subgroup differences: Chi² = 0.33, df = 1 (P = 0.57), I² = 0%,
Analysis 3.1; Chi² = 0.00, df = 1 (P = 0.96), I² = 0%, Analysis 3.2;
Chi² = 1.15, df = 1 (P = 0.28), I² = 12.7%, Analysis 3.3; Chi² =
0.14, df = 1 (P = 0.70), I² = 0%, Analysis 3.4; Chi² = 0.20, df = 1
(P = 0.66), I² = 0%, Analysis 3.5.
Other subgroups - women with chorioamnionitis
preoperatively versus women without chorioamnionitis;
women undergoing emergency cesarean versus those
undergoing unscheduled cesarean versus those undergoing
scheduled cesarean; women with internal fetal or uterine
monitors in place versus those with only external monitors in
place before the cesarean
Neither of the two trials that included women diagnosed with
chorioamnionitis stratified their data based on the presence or ab-
sence of chorioamnionitis. Neither of the two trials that did not ex-
clude women undergoing emergency cesarean stratified their data
based on emergency cesarean versus unscheduled versus scheduled
cesarean. In addition, while two trials reported on the presence
of internal monitoring (Haas 2010; Starr 2005), none of them
stratified their outcome data based on this variable. Thus we did
not perform these three subgroup analyses.
No adverse events were noted in any of the trials from the vaginal
preparation solution.
D I S C U S S I O N
Summary of main results
Vaginal cleansing with povidone-iodine solutions before cesarean
delivery can reduce the incidence of post-cesarean endometritis.
The heterogeneity in the results for this variable may be explain-
able by the study design and patient populations. The Guzman
2002 study used a placebo vaginal saline wash. This may have led
to a lower baseline incidence of postoperative morbidity. TheHaas
2010 study contained a majority of women who were obtaining
planned repeat cesarean deliveries, a group known to be at lower
risk for postoperative infectious morbidities. The subgroup analy-
ses demonstrated that the reduction in postoperative endometritis
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is most pronounced for women with ruptured membranes. This
subgroup analysis should be interpreted with caution, however,
as the number of participants and events is low. Thus, the in-
tervention may be particularly useful for cesareans performed for
women who have ruptured membranes. Ruptured membranes are
a known risk factor for post-cesarean infectious morbidity. The
use of vaginal preparation in women with ruptured membranes
thus makes particular sense.
Overall completeness and applicability of
evidence
The evidence is relatively complete, consistent, and highly appli-
cable to clinical care.
Quality of the evidence
The risk of bias of the five included trials is reasonably low, with
very few areas being identified as potential sources of bias (Figure
1; Figure 2). The agreement of the trial data in general and the
large number of participants represented lend validity to the re-
sults of the meta-analysis. The clinical heterogeneity was essen-
tially eliminated in the subgroup analyses, the results of which
were consistent with the overall group results. Thus, fixed-effect
modeling was retained in the overall results. The quality of the
evidence using GRADE was low for post-cesarean endometritis
due to high heterogeneity and a small sample size, moderate for
postoperative fever due to the confidence interval crossing the line
of no effect, and low for wound infection due to optimal infor-
mation size that was not met (Summary of findings for the main
comparison).
Potential biases in the review process
There is always potential that the review process was biased. How-
ever, the trial search yielded several studies. The study evaluation
and data extraction were performed by three review authors with
almost no discrepancies that needed to be resolved by consensus.
Thus there is a minimal risk of bias in the review process. The
studies were carried out in both developed and developing coun-
tries.
Agreements and disagreements with other
studies or reviews
This review is limited by the somewhat small number of trials
of preoperative vaginal preparation immediately before cesarean
delivery. Because cesarean deliveries are so commonly performed
and this intervention would seem to be an inexpensive, simple
intervention to reduce post-cesarean infectious morbidities, it was
surprising to find such a paucity of randomized trial data. While
the data point to a reduction in post-cesarean endometritis with
the intervention, it is possible that with more trial data, the trends
towards other reduced infectious morbidity would also become
statistically significant. Uniformity in the reporting of the data
outcomes and the subgroup data stratification would have also
aided this review.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Vaginal preparation with povidone-iodine solution immediately
before cesarean delivery reduces the risk of postoperative en-
dometritis. No adverse effects were noted in any of the trials. This
benefit is particularly realized for women undergoing cesarean de-
livery with ruptured membranes. As a simple, generally inexpen-
sive intervention, providers should consider implementing preop-
erative vaginal cleansing with povidone-iodine before performing
cesarean deliveries. Information on whether other methods of, or
solutions for, vaginal preparation is lacking.
Implications for research
As practice changes and providers begin to routinely implement
preoperative vaginal cleansing before cesarean deliveries, postoper-
ative infectious morbidities should be tracked and compared with
the same outcomes before the practice change. Any adverse events
realized with implementation should be reported.
A C K N OW L E D G E M E N T S
The authors thank Dr Jon Hathaway for his independent assess-
ment of trial quality and data extraction for the Haas 2010 study
and Erika Ota for preparing the ’Summary of findings’ table.
Erika Ota’s work was financially supported by the UNDP/
UNFPA/UNICEF/WHO/World Bank Special Programme of Re-
search,Development andResearchTraining inHumanReproduc-
tion (HRP), Department of Reproductive Health and Research
(RHR), World Health Organization. The named authors are re-
sponsible for the views expressed in this publication.
As part of the pre-publication editorial process, this review has
been commented on by three peers (an editor and two referees
who are external to the editorial team), a member of the Pregnancy
and Childbirth Group’s international panel of consumers and the
Group’s Statistical Adviser.
14Vaginal preparation with antiseptic solution before cesarean section for preventing postoperative infections (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
R E F E R E N C E S
References to studies included in this review
Asghania 2011 {published data only}
∗ Asghania M, Mirblouk F, Shakiba M, Faraji R.
Preoperative vaginal preparation with povidone-iodine on
post-caesarean infectious morbidity. Journal of Obstetrics
and Gynaecology 2011;31(5):400–3.
Asgharnia M. The effect of preoperative vaginal povidone
iodine preparation on post cesarean infection. IRCT
Iranian Registry of Clinical Trials (www.irct.ir) (accessed 6
December 2010).
Guzman 2002 {published data only}
Guzman MA, Prien SD, Blann DW. Post-cesarean related
infection and vaginal preparation with povidone-iodine
revisited. Primary Care Update for OB/GYNS 2002;9(6):
206–9.
Haas 2010 {published data only}
Haas DM. Vaginal cleansing at cesarean delivery to
reduce infection: a randomized, controlled trial. http://
clinicaltrials.gov/ct2/show/NCT00386477 (accessed 20
February 2008).
∗ Haas DM, Pazouki F, Smith RR, Fry AM, Podzielinski
I, Al-Darei SM, et al.Vaginal cleansing before cesarean
delivery to reduce postoperative infectious morbidity: a
randomized, controlled trial. American Journal of Obstetrics
and Gynecology 2010;202(3):310.e1–6.
Reid 2001 {published data only}
Reid GC, Hartmann KE, MacMahon MJ. Can postpartum
infectious morbidity be decreased by vaginal preparation
with povidone iodine prior to cesarean delivery?. American
Journal of Obstetrics and Gynecology 2000;182(1 Pt 2):S96.
∗ Reid VC, Hartmann KE, McMahon M, Fry EP. Vaginal
preparation with povidone iodine and postcesarean
infectious morbidity: a randomized controlled trial.
Obstetrics & Gynecology 2001;97:147–52.
Starr 2005 {published data only}
Agbunag R. Preoperative vaginal preparation with povidone-
iodine decreases the risk of post-cesarean endometritis.
American Journal of Obstetrics and Gynecology 2001;184(1):
S182.
∗ Starr RV, Zurawski J, Ismail M. Preoperative vaginal
preparation with povidone-iodine and the risk of
postcesarean endometritis. Obstetrics & Gynecology 2005;
105(5 Pt 1):1024–9.
Additional references
Disgupta 1988
Disgupta RK, Rao RS, Rjaram P, Natarajan MK. Anaerobic
infections in pregnant women undergoing cesarean section
and associated risk factors. Asia-Oceania Journal of Obstetrics
and Gynaecology 1988;14:437–41.
Duignan 1975
Duignan NM, Lowe PH. Pre-operative disinfection of the
vagina. Journal of Antimicrobial Chemotherapy 1975;1:
117–20.
French 2004
French LM, Smaill FM. Antibiotic regimens for endometritis
after delivery. Cochrane Database of Systematic Reviews 2004,
Issue 4. [DOI: 10.1002/14651858.CD001067.pub2]
Gibbs 1982
Gibbs RS, Blanco JD, St. Clair PJ, Castanda YS. Vaginal
colonization with resistant aerobic bacteria after antibiotic
therapy for endometritis. American Journal of Obstetrics and
Gynecology 1982;142:130–4.
Grade 2008
Brozek J, Oxman A, Schünemann H. GRADEpro. 3.6.
The Cochrane Collaboration, 2008.
Graham 1993
Graham JM, Blanco JD, Oshiro BT, Magee KP, Monga
M, Eriksen N. Single-dose ampicillin prophylaxis does
not eradicate enterococcus from the lower genital tract.
Obstetrics & Gynecology 1993;81:115–7.
Haeri 1984
Haeri AD, Kloppers LL, Forder AA, Baillie P. Effect of
different pre-operative vaginal preparations on morbidity of
patients undergoing abdominal hysterectomy. South African
Medical Journal 1984;50:80–2.
Higgins 2008
Higgins JPT, Green S, editors. Cochrane Handbook for
Systematic Reviews of Interventions Version 5.0.1 [updated
September 2008]. The Cochrane Collaboration, 2008.
Available from www.cochrane-handbook.org.
Higgins 2011
Higgins JPT, Green S, editors. Cochrane Handbook for
Systematic Reviews of Interventions Version 5.1.0 [updated
March 2011]. The Cochrane Collaboration, 2011.
Available from www.cochrane-handbook.org.
Hofmeyr 2002
Hofmeyr GJ, Smaill FM. Antibiotic prophylaxis for cesarean
section. Cochrane Database of Systematic Reviews 2002, Issue
3. [DOI: 10.1002/14651858.CD000933]
Martens 1991
Martens MG, Faro S, Maccato M, Riddle G, Hammill HA.
Susceptibility of female pelvic pathogens to oral antibiotic
agents in patients who develop postpartum endometritis.
American Journal of Obstetrics and Gynecology 1991;164:
1383–6.
RevMan 2014
The Nordic Cochrane Centre, The Cochrane Collaboration.
Review Manager (RevMan). 5.3. Copenhagen: The Nordic
Cochrane Centre, The Cochrane Collaboration, 2014.
Schunemann 2009
Schunemann HJ. GRADE: from grading the evidence
to developing recommendations. A description of the
system and a proposal regarding the transferability of the
results of clinical research to clinical practice [GRADE:
Von der Evidenz zur Empfehlung. Beschreibung des
Systems und Losungsbeitrag zur Ubertragbarkeit von
15Vaginal preparation with antiseptic solution before cesarean section for preventing postoperative infections (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Studienergebnissen]. Zeitschrift fur Evidenz, Fortbildung
und Qualitat im Gesundheitswesen 2009;103(6):391–400.
[PUBMED: 19839216]
Stiver 1984
Stiver HG, Forward KR, Tyrrell DL, Krip G, Livingstone
RA, Fugere P, et al.Comparative cervical microflora shifts
after cefoxitin or cefazolin prophylaxis against infection
following cesarean section. American Journal of Obstetrics
and Gynecology 1984;149:718–21.
Watts 1991
Watts DH, Hillier SL, Eschenbach DA. Upper genital tract
isolates at delivery as predictors of post-cesarean infections
among women receiving antibiotic prophylaxis. Obstetrics
& Gynecology 1991;77:287–92.
Yokoe 2001
Yokoe DS, Christiansen CL, Johnson R, Sands KE,
Livingston J, Shtatland ES, et al.Epidemiology of and
surveillance for postpartum infections. Emerging Infectious
Diseases 2001;7:837–41.
Yonekura 1985
Yonekura ML. Risk factors for postcesarean
endomyometritis. American Journal of Medicine 1985;78:
177–87.
References to other published versions of this review
Haas 2009
Haas DM, Al Darei S, Contreras K. Vaginal preparation
with antiseptic solution before cesarean section for
preventing postoperative infections. Cochrane Database
of Systematic Reviews 2009, Issue 3. [DOI: 10.1002/
14651858.CD007892]
Haas 2010a
Haas DM, Morgan Al Darei S, Contreras K. Vaginal
preparation with antiseptic solution before cesarean section
for preventing postoperative infections. Cochrane Database
of Systematic Reviews 2010, Issue 3. [DOI: 10.1002/
14651858.CD007892.pub2]
Haas 2013
Haas DM, Morgan S, Contreras K. Vaginal preparation
with antiseptic solution before cesarean section for
preventing postoperative infections. Cochrane Database
of Systematic Reviews 2013, Issue 1. [DOI: 10.1002/
14651858.CD007892.pub3]
∗ Indicates the major publication for the study
16Vaginal preparation with antiseptic solution before cesarean section for preventing postoperative infections (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Asghania 2011
Methods Double blind quasi-RCT.
Participants Women undergoing non-emergent or laboring cesarean delivery.
Interventions Two 4x4 gauze sponges soaked in 10% povidone iodine solutions rotated 360 degrees
for 30 seconds from vault to introitus vs. no vaginal scrub
Outcomes Febrile morbidity, endometritis, wound infection.
Notes May 2007-April 2008.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Quasi-randomized, alternating sequence.
Allocation concealment (selection bias) High risk Quasi-randomized, alternating sequence.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Participants: unclear.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcome assessors blinded.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Complete outcome data.
Selective reporting (reporting bias) Low risk No evidence of selective reporting.
Other bias High risk Large differences in baseline characteristics- more exami-
nations, longer labor, more preterm, longer surgery, longer
duration of PROM in vaginal cleansing group
17Vaginal preparation with antiseptic solution before cesarean section for preventing postoperative infections (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Guzman 2002
Methods RCT.
Participants 160 women undergoing cesarean delivery (80 intervention, 80 control)
Interventions Intervention: povidone-iodine vaginal wash (concentration not specified)
Control: saline vaginal wash.
Outcomes Endometritis (temperature > 100.4 degrees F at least twice > 24 hours after surgery or
of 101 degrees F any time after surgery, with abdominal/uterine tenderness)
Cellulitis (advancing erythema around the incision).
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not specified.
Allocation concealment (selection bias) Unclear risk Not specified.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Cleansing done by nurse while providers outside and thus
providers were blinded to the intervention
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcomes assessors blinded.
Incomplete outcome data (attrition bias)
All outcomes
Low risk No incomplete outcome data.
Selective reporting (reporting bias) Low risk No evidence of selective reporting.
Other bias Low risk No evidence of other bias.
Haas 2010
Methods RCT.
Participants 300 participants (155 intervention, 145 control) received vaginal cleansing or nothing
directly before cesarean delivery, age ≥ 18 years
Interventions Intervention: preoperative vaginal cleansing with 1% povidone iodine scrubs
Control: no preoperative vaginal cleansing.
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Haas 2010 (Continued)
Outcomes Post-cesarean endometritis (uterine tenderness plus postoperative fever requiring antibi-
otics)
Postoperative fever (> 38 degrees Celcius, > 24 hours after surgery)
Wound infection requiring antibiotics.
Wound separation, seroma, hematoma, or need for debridement.
Composite infectious morbidity outcome: either endometritis, fever, sepsis, hospital
readmission, wound infection, or wound complication
Notes Internally funded.
The trial was stopped early due to difficulty recruiting.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated random number table, replacement ran-
domization
Allocation concealment (selection bias) Low risk Sequentially numbered opaque security envelopes.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Not specifically blinded but after anesthesia care providers did
not necessarily know group
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcomes assessor only.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Appeared to be complete data on all participants.
Selective reporting (reporting bias) Low risk No evidence of selective reporting.
Other bias Unclear risk Trial stopped early at safety analysis due to difficulty recruiting
and effect seen
Reid 2001
Methods RCT.
Participants 501 women admitted and mentally competent to consent for a cesarean delivery (250
intervention, 251 control)
Interventions Intervention: 10% povidone-iodine surgical scrub solution vaginally immediately before
cesarean
Control: no preparation.
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Reid 2001 (Continued)
Outcomes Fever (38C or greater after the day of surgery).
Febrile morbidity (postoperative fever on 2 or more calendar days, excluding the day of
surgery)
Endometritis (postoperative fever, with a physician’s note indicatinguterine or abdominal
pain or tenderness, preceding an order for antibiotics and a statement indicating that the
antibiotics were for uterine or pelvic infection and laboratory studies did not indicate
other source for the infection)
Wound separation (defined by chart note reporting separation of the operative incision
requiring intervention)
Number of postoperative days with fever.
Average duration of antibiotic administration.
Length of hospitalization.
Notes Chorioamnionitis participants excluded from analysis.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated, permuted block randomization schedule.
Allocation concealment (selection bias) Low risk Opaque sealed and numbered envelopes taped to abdominal
prep packs
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not specifically stated. Cleansing done by residents during rou-
tine prep. These may have been the same surgeons who did the
surgery and postoperative care
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcomes assessor masked.
Incomplete outcome data (attrition bias)
All outcomes
High risk Excluded 68 women post-hoc with antenatal chorioamnionitis
because inclusion distorted the absolute rates of fever and infec-
tious complications
Selective reporting (reporting bias) High risk One trial (Reid 2001) had a large number of participants ex-
cluded after randomization who had chorioamnionitis (a known
risk factor for postoperative infectious morbidity) because their
inclusion “distorted the absolute rates of fever and infectious
morbidity.” That trial states that when the 68 participants with
antepartum infection were included, the estimates of effect of
vaginal preparation were not meaningfully different. Thus they
planned to exclude those participants from reports of outcomes.
As this represented 13.5% of the originally randomized sample,
however, there is a risk that this introduced selective reporting
bias into the trial (Reid 2001).
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Reid 2001 (Continued)
Other bias Low risk No evidence of other bias.
Starr 2005
Methods RCT.
Participants 400 women to undergo non-emergency cesarean delivery (142 intervention, 166 control
analyzed)
Interventions Intervention: pre-packaged povidone-iodine solution (EZ Prep 200, 5%) vaginal prepa-
ration for 30 seconds
Control: no preoperative vaginal preparation.
Outcomes Febrile morbidity (any postoperative temperature > 38C).
Endometritis (temperature elevation > 38C beyond the first postoperative day, in as-
sociation with uterine tenderness and foul lochia, in the absence of evidence of other
infection; given at the time of clinical evaluation)
Wound infection (clinical diagnosis evidenced by erythema or wound edge separation
with purulent drainage; including wound dehiscence and necrotizing fasciitis and ex-
cluding skin separation without evidence of cellulitis)
Notes Excluded chorioamnionitis and placenta previa.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random digit table.
Allocation concealment (selection bias) Low risk Sequentially numbered, opaque, sealed envelopes.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Not stated for participants but treating providers at the time of
fever were unaware of participation status
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Chart reviewer unaware of group.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Ultimately 92 participants excluded from analysis, reasons ex-
plained. Unclear if exclusions impacted data
Selective reporting (reporting bias) Unclear risk One other trial had a potential selective reporting bias (Starr
2005). Of 400 participants randomized, 92 (23%) were ex-
cluded after randomization: 33 due to lost envelopes, 6 for vio-
lations of inclusion criteria, and 53 because their hospital charts
could not be located. Of all the women excluded, 54 were in the
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Starr 2005 (Continued)
vaginal cleansing group and 38 were in the control group. Only
outcomes for women for whom all data were available were re-
ported. The large number of women excluded also makes this
trial subject to an unclear risk of bias, however as there is no
outcome data for the excluded participants, the potential impact
is unclear (Starr 2005).
Other bias Low risk No evidence of other bias.
PROM: premature rupture of membranes
RCT: randomized controlled trial
vs: versus
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D A T A A N D A N A L Y S E S
Comparison 1. Vaginal preparation versus control
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Post-cesarean endometritis 5 1766 Risk Ratio (M-H, Random, 95% CI) 0.39 [0.16, 0.97]
2 Postoperative fever 4 1606 Risk Ratio (M-H, Fixed, 95% CI) 0.92 [0.71, 1.18]
3 Wound infection 4 1336 Risk Ratio (M-H, Fixed, 95% CI) 0.99 [0.57, 1.70]
4 Any wound complication 2 729 Risk Ratio (M-H, Fixed, 95% CI) 0.63 [0.37, 1.07]
5 Composite wound complication
or endometritis
1 299 Risk Ratio (M-H, Fixed, 95% CI) 0.55 [0.26, 1.15]
Comparison 2. Vaginal preparation versus control - stratified by presence of labor
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Post-cesarean endometritis 2 725 Risk Ratio (M-H, Random, 95% CI) 0.93 [0.36, 2.44]
1.1 Women in labor 2 311 Risk Ratio (M-H, Random, 95% CI) 0.63 [0.18, 2.25]
1.2 Women not in labor 2 414 Risk Ratio (M-H, Random, 95% CI) 1.40 [0.20, 9.86]
2 Postoperative fever 1 296 Risk Ratio (M-H, Fixed, 95% CI) 0.28 [0.06, 1.37]
2.1 Women in labor 1 95 Risk Ratio (M-H, Fixed, 95% CI) 0.22 [0.03, 1.83]
2.2 Women not in labor 1 201 Risk Ratio (M-H, Fixed, 95% CI) 0.42 [0.04, 4.58]
3 Wound infection 1 290 Risk Ratio (M-H, Fixed, 95% CI) 0.67 [0.26, 1.71]
3.1 Women in labor 1 95 Risk Ratio (M-H, Fixed, 95% CI) 0.67 [0.17, 2.63]
3.2 Women not in labor 1 195 Risk Ratio (M-H, Fixed, 95% CI) 0.67 [0.19, 2.43]
4 Any wound complication 2 729 Risk Ratio (M-H, Fixed, 95% CI) 0.64 [0.38, 1.09]
4.1 Women in labor 2 314 Risk Ratio (M-H, Fixed, 95% CI) 0.77 [0.36, 1.61]
4.2 Women not in labor 2 415 Risk Ratio (M-H, Fixed, 95% CI) 0.54 [0.25, 1.16]
5 Composite wound complication
or endometritis
1 299 Risk Ratio (M-H, Fixed, 95% CI) 0.58 [0.27, 1.23]
5.1 Women in labor 1 95 Risk Ratio (M-H, Fixed, 95% CI) 0.40 [0.14, 1.18]
5.2 Women not in labor 1 204 Risk Ratio (M-H, Fixed, 95% CI) 0.85 [0.29, 2.56]
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Comparison 3. Vaginal preparation versus control - stratified by presence of ruptured membranes
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Post-cesarean endometritis 2 460 Risk Ratio (M-H, Fixed, 95% CI) 0.17 [0.05, 0.56]
1.1 Women with ruptured
membranes
2 148 Risk Ratio (M-H, Fixed, 95% CI) 0.13 [0.02, 0.66]
1.2 Women with intact
membranes
2 312 Risk Ratio (M-H, Fixed, 95% CI) 0.26 [0.04, 1.51]
2 Postoperative fever 1 300 Risk Ratio (M-H, Fixed, 95% CI) 0.30 [0.06, 1.40]
2.1 Women with ruptured
membranes
1 76 Risk Ratio (M-H, Fixed, 95% CI) 0.31 [0.04, 2.64]
2.2 Women with intact
membranes
1 224 Risk Ratio (M-H, Fixed, 95% CI) 0.28 [0.03, 2.69]
3 Wound infection 2 460 Risk Ratio (M-H, Fixed, 95% CI) 1.00 [0.48, 2.06]
3.1 Women with ruptured
membranes
2 148 Risk Ratio (M-H, Fixed, 95% CI) 1.5 [0.52, 4.32]
3.2 Women with intact
membranes
2 312 Risk Ratio (M-H, Fixed, 95% CI) 0.67 [0.23, 1.89]
4 Any wound complication 1 300 Risk Ratio (M-H, Fixed, 95% CI) 0.64 [0.28, 1.44]
4.1 Women with ruptured
membranes
1 76 Risk Ratio (M-H, Fixed, 95% CI) 0.53 [0.15, 1.89]
4.2 Women with intact
membranes
1 224 Risk Ratio (M-H, Fixed, 95% CI) 0.73 [0.25, 2.10]
5 Composite wound complication
or endometritis
1 300 Risk Ratio (M-H, Fixed, 95% CI) 0.58 [0.27, 1.23]
5.1 Women with ruptured
membranes
1 76 Risk Ratio (M-H, Fixed, 95% CI) 0.46 [0.13, 1.61]
5.2 Women with intact
membranes
1 224 Risk Ratio (M-H, Fixed, 95% CI) 0.66 [0.26, 1.72]
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Analysis 1.1. Comparison 1 Vaginal preparation versus control, Outcome 1 Post-cesarean endometritis.
Review: Vaginal preparation with antiseptic solution before cesarean section for preventing postoperative infections
Comparison: 1 Vaginal preparation versus control
Outcome: 1 Post-cesarean endometritis
Study or subgroup Vaginal preparation Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Asghania 2011 1/284 7/284 12.4 % 0.14 [ 0.02, 1.15 ]
Guzman 2002 2/80 13/80 18.8 % 0.15 [ 0.04, 0.66 ]
Haas 2010 0/155 4/145 7.7 % 0.10 [ 0.01, 1.91 ]
Reid 2001 19/217 16/213 31.0 % 1.17 [ 0.62, 2.21 ]
Starr 2005 10/142 24/166 30.0 % 0.49 [ 0.24, 0.98 ]
Total (95% CI) 878 888 100.0 % 0.39 [ 0.16, 0.97 ]
Total events: 32 (Vaginal preparation), 64 (Control)
Heterogeneity: Tau2 = 0.58; Chi2 = 11.45, df = 4 (P = 0.02); I2 =65%
Test for overall effect: Z = 2.03 (P = 0.043)
Test for subgroup differences: Not applicable
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Favors vaginal Favors control
25Vaginal preparation with antiseptic solution before cesarean section for preventing postoperative infections (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.2. Comparison 1 Vaginal preparation versus control, Outcome 2 Postoperative fever.
Review: Vaginal preparation with antiseptic solution before cesarean section for preventing postoperative infections
Comparison: 1 Vaginal preparation versus control
Outcome: 2 Postoperative fever
Study or subgroup Vaginal preparation Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Asghania 2011 14/284 17/284 16.2 % 0.82 [ 0.41, 1.64 ]
Haas 2010 2/155 7/145 6.9 % 0.27 [ 0.06, 1.27 ]
Reid 2001 44/217 37/213 35.6 % 1.17 [ 0.79, 1.73 ]
Starr 2005 34/142 47/166 41.3 % 0.85 [ 0.58, 1.24 ]
Total (95% CI) 798 808 100.0 % 0.92 [ 0.71, 1.18 ]
Total events: 94 (Vaginal preparation), 108 (Control)
Heterogeneity: Chi2 = 4.12, df = 3 (P = 0.25); I2 =27%
Test for overall effect: Z = 0.68 (P = 0.49)
Test for subgroup differences: Not applicable
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Analysis 1.3. Comparison 1 Vaginal preparation versus control, Outcome 3 Wound infection.
Review: Vaginal preparation with antiseptic solution before cesarean section for preventing postoperative infections
Comparison: 1 Vaginal preparation versus control
Outcome: 3 Wound infection
Study or subgroup Vaginal preparation Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Asghania 2011 10/284 9/284 35.7 % 1.11 [ 0.46, 2.69 ]
Guzman 2002 7/80 4/80 15.9 % 1.75 [ 0.53, 5.75 ]
Haas 2010 7/155 10/145 41.0 % 0.65 [ 0.26, 1.67 ]
Starr 2005 1/142 2/166 7.3 % 0.58 [ 0.05, 6.38 ]
Total (95% CI) 661 675 100.0 % 0.99 [ 0.57, 1.70 ]
Total events: 25 (Vaginal preparation), 25 (Control)
Heterogeneity: Chi2 = 1.88, df = 3 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 0.05 (P = 0.96)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
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Analysis 1.4. Comparison 1 Vaginal preparation versus control, Outcome 4 Any wound complication.
Review: Vaginal preparation with antiseptic solution before cesarean section for preventing postoperative infections
Comparison: 1 Vaginal preparation versus control
Outcome: 4 Any wound complication
Study or subgroup Vaginal preparation Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Haas 2010 9/155 14/144 44.4 % 0.60 [ 0.27, 1.34 ]
Reid 2001 12/217 18/213 55.6 % 0.65 [ 0.32, 1.33 ]
Total (95% CI) 372 357 100.0 % 0.63 [ 0.37, 1.07 ]
Total events: 21 (Vaginal preparation), 32 (Control)
Heterogeneity: Chi2 = 0.03, df = 1 (P = 0.87); I2 =0.0%
Test for overall effect: Z = 1.71 (P = 0.087)
Test for subgroup differences: Not applicable
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Analysis 1.5. Comparison 1 Vaginal preparation versus control, Outcome 5 Composite wound complication
or endometritis.
Review: Vaginal preparation with antiseptic solution before cesarean section for preventing postoperative infections
Comparison: 1 Vaginal preparation versus control
Outcome: 5 Composite wound complication or endometritis
Study or subgroup Vaginal preparation Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Haas 2010 10/155 17/144 100.0 % 0.55 [ 0.26, 1.15 ]
Total (95% CI) 155 144 100.0 % 0.55 [ 0.26, 1.15 ]
Total events: 10 (Vaginal preparation), 17 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.58 (P = 0.11)
Test for subgroup differences: Not applicable
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Analysis 2.1. Comparison 2 Vaginal preparation versus control - stratified by presence of labor, Outcome 1
Post-cesarean endometritis.
Review: Vaginal preparation with antiseptic solution before cesarean section for preventing postoperative infections
Comparison: 2 Vaginal preparation versus control - stratified by presence of labor
Outcome: 1 Post-cesarean endometritis
Study or subgroup Vaginal preparation Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Women in labor
Haas 2010 0/45 3/47 9.3 % 0.15 [ 0.01, 2.81 ]
Reid 2001 11/110 13/109 51.0 % 0.84 [ 0.39, 1.79 ]
Subtotal (95% CI) 155 156 60.4 % 0.63 [ 0.18, 2.25 ]
Total events: 11 (Vaginal preparation), 16 (Control)
Heterogeneity: Tau2 = 0.35; Chi2 = 1.29, df = 1 (P = 0.26); I2 =23%
Test for overall effect: Z = 0.70 (P = 0.48)
2 Women not in labor
Haas 2010 0/110 1/93 8.1 % 0.28 [ 0.01, 6.85 ]
Reid 2001 8/107 3/104 31.6 % 2.59 [ 0.71, 9.50 ]
Subtotal (95% CI) 217 197 39.6 % 1.40 [ 0.20, 9.86 ]
Total events: 8 (Vaginal preparation), 4 (Control)
Heterogeneity: Tau2 = 0.93; Chi2 = 1.60, df = 1 (P = 0.21); I2 =38%
Test for overall effect: Z = 0.34 (P = 0.73)
Total (95% CI) 372 353 100.0 % 0.93 [ 0.36, 2.44 ]
Total events: 19 (Vaginal preparation), 20 (Control)
Heterogeneity: Tau2 = 0.32; Chi2 = 4.49, df = 3 (P = 0.21); I2 =33%
Test for overall effect: Z = 0.14 (P = 0.89)
Test for subgroup differences: Chi2 = 0.45, df = 1 (P = 0.50), I2 =0.0%
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Analysis 2.2. Comparison 2 Vaginal preparation versus control - stratified by presence of labor, Outcome 2
Postoperative fever.
Review: Vaginal preparation with antiseptic solution before cesarean section for preventing postoperative infections
Comparison: 2 Vaginal preparation versus control - stratified by presence of labor
Outcome: 2 Postoperative fever
Study or subgroup Vaginal preparation Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Women in labor
Haas 2010 1/45 5/50 68.6 % 0.22 [ 0.03, 1.83 ]
Subtotal (95% CI) 45 50 68.6 % 0.22 [ 0.03, 1.83 ]
Total events: 1 (Vaginal preparation), 5 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.40 (P = 0.16)
2 Women not in labor
Haas 2010 1/109 2/92 31.4 % 0.42 [ 0.04, 4.58 ]
Subtotal (95% CI) 109 92 31.4 % 0.42 [ 0.04, 4.58 ]
Total events: 1 (Vaginal preparation), 2 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.71 (P = 0.48)
Total (95% CI) 154 142 100.0 % 0.28 [ 0.06, 1.37 ]
Total events: 2 (Vaginal preparation), 7 (Control)
Heterogeneity: Chi2 = 0.16, df = 1 (P = 0.69); I2 =0.0%
Test for overall effect: Z = 1.57 (P = 0.12)
Test for subgroup differences: Chi2 = 0.16, df = 1 (P = 0.69), I2 =0.0%
0.01 0.1 1 10 100
Favors vaginal Favors control
30Vaginal preparation with antiseptic solution before cesarean section for preventing postoperative infections (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 2.3. Comparison 2 Vaginal preparation versus control - stratified by presence of labor, Outcome 3
Wound infection.
Review: Vaginal preparation with antiseptic solution before cesarean section for preventing postoperative infections
Comparison: 2 Vaginal preparation versus control - stratified by presence of labor
Outcome: 3 Wound infection
Study or subgroup Vaginal preparation Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Women in labor
Haas 2010 3/45 5/50 46.6 % 0.67 [ 0.17, 2.63 ]
Subtotal (95% CI) 45 50 46.6 % 0.67 [ 0.17, 2.63 ]
Total events: 3 (Vaginal preparation), 5 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.58 (P = 0.56)
2 Women not in labor
Haas 2010 4/106 5/89 53.4 % 0.67 [ 0.19, 2.43 ]
Subtotal (95% CI) 106 89 53.4 % 0.67 [ 0.19, 2.43 ]
Total events: 4 (Vaginal preparation), 5 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.61 (P = 0.54)
Total (95% CI) 151 139 100.0 % 0.67 [ 0.26, 1.71 ]
Total events: 7 (Vaginal preparation), 10 (Control)
Heterogeneity: Chi2 = 0.00, df = 1 (P = 0.99); I2 =0.0%
Test for overall effect: Z = 0.84 (P = 0.40)
Test for subgroup differences: Chi2 = 0.00, df = 1 (P = 0.99), I2 =0.0%
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Analysis 2.4. Comparison 2 Vaginal preparation versus control - stratified by presence of labor, Outcome 4
Any wound complication.
Review: Vaginal preparation with antiseptic solution before cesarean section for preventing postoperative infections
Comparison: 2 Vaginal preparation versus control - stratified by presence of labor
Outcome: 4 Any wound complication
Study or subgroup Vaginal preparation Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Women in labor
Haas 2010 4/45 8/50 23.5 % 0.56 [ 0.18, 1.72 ]
Reid 2001 7/110 7/109 21.8 % 0.99 [ 0.36, 2.73 ]
Subtotal (95% CI) 155 159 45.3 % 0.77 [ 0.36, 1.61 ]
Total events: 11 (Vaginal preparation), 15 (Control)
Heterogeneity: Chi2 = 0.56, df = 1 (P = 0.46); I2 =0.0%
Test for overall effect: Z = 0.70 (P = 0.48)
2 Women not in labor
Haas 2010 5/110 6/94 20.1 % 0.71 [ 0.22, 2.26 ]
Reid 2001 5/107 11/104 34.6 % 0.44 [ 0.16, 1.23 ]
Subtotal (95% CI) 217 198 54.7 % 0.54 [ 0.25, 1.16 ]
Total events: 10 (Vaginal preparation), 17 (Control)
Heterogeneity: Chi2 = 0.37, df = 1 (P = 0.54); I2 =0.0%
Test for overall effect: Z = 1.58 (P = 0.11)
Total (95% CI) 372 357 100.0 % 0.64 [ 0.38, 1.09 ]
Total events: 21 (Vaginal preparation), 32 (Control)
Heterogeneity: Chi2 = 1.31, df = 3 (P = 0.73); I2 =0.0%
Test for overall effect: Z = 1.63 (P = 0.10)
Test for subgroup differences: Chi2 = 0.41, df = 1 (P = 0.52), I2 =0.0%
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Analysis 2.5. Comparison 2 Vaginal preparation versus control - stratified by presence of labor, Outcome 5
Composite wound complication or endometritis.
Review: Vaginal preparation with antiseptic solution before cesarean section for preventing postoperative infections
Comparison: 2 Vaginal preparation versus control - stratified by presence of labor
Outcome: 5 Composite wound complication or endometritis
Study or subgroup Vaginal preparation Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Women in labor
Haas 2010 4/45 11/50 61.7 % 0.40 [ 0.14, 1.18 ]
Subtotal (95% CI) 45 50 61.7 % 0.40 [ 0.14, 1.18 ]
Total events: 4 (Vaginal preparation), 11 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.66 (P = 0.097)
2 Women not in labor
Haas 2010 6/110 6/94 38.3 % 0.85 [ 0.29, 2.56 ]
Subtotal (95% CI) 110 94 38.3 % 0.85 [ 0.29, 2.56 ]
Total events: 6 (Vaginal preparation), 6 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.28 (P = 0.78)
Total (95% CI) 155 144 100.0 % 0.58 [ 0.27, 1.23 ]
Total events: 10 (Vaginal preparation), 17 (Control)
Heterogeneity: Chi2 = 0.92, df = 1 (P = 0.34); I2 =0.0%
Test for overall effect: Z = 1.43 (P = 0.15)
Test for subgroup differences: Chi2 = 0.92, df = 1 (P = 0.34), I2 =0.0%
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Analysis 3.1. Comparison 3 Vaginal preparation versus control - stratified by presence of ruptured
membranes, Outcome 1 Post-cesarean endometritis.
Review: Vaginal preparation with antiseptic solution before cesarean section for preventing postoperative infections
Comparison: 3 Vaginal preparation versus control - stratified by presence of ruptured membranes
Outcome: 1 Post-cesarean endometritis
Study or subgroup Vaginal cleansing Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Women with ruptured membranes
Guzman 2002 1/36 10/36 55.7 % 0.10 [ 0.01, 0.74 ]
Haas 2010 0/34 2/42 12.5 % 0.25 [ 0.01, 4.95 ]
Subtotal (95% CI) 70 78 68.2 % 0.13 [ 0.02, 0.66 ]
Total events: 1 (Vaginal cleansing), 12 (Control)
Heterogeneity: Chi2 = 0.24, df = 1 (P = 0.62); I2 =0.0%
Test for overall effect: Z = 2.46 (P = 0.014)
2 Women with intact membranes
Guzman 2002 1/44 3/44 16.7 % 0.33 [ 0.04, 3.08 ]
Haas 2010 0/121 2/103 15.0 % 0.17 [ 0.01, 3.51 ]
Subtotal (95% CI) 165 147 31.8 % 0.26 [ 0.04, 1.51 ]
Total events: 1 (Vaginal cleansing), 5 (Control)
Heterogeneity: Chi2 = 0.12, df = 1 (P = 0.73); I2 =0.0%
Test for overall effect: Z = 1.50 (P = 0.13)
Total (95% CI) 235 225 100.0 % 0.17 [ 0.05, 0.56 ]
Total events: 2 (Vaginal cleansing), 17 (Control)
Heterogeneity: Chi2 = 0.68, df = 3 (P = 0.88); I2 =0.0%
Test for overall effect: Z = 2.92 (P = 0.0035)
Test for subgroup differences: Chi2 = 0.33, df = 1 (P = 0.57), I2 =0.0%
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Analysis 3.2. Comparison 3 Vaginal preparation versus control - stratified by presence of ruptured
membranes, Outcome 2 Postoperative fever.
Review: Vaginal preparation with antiseptic solution before cesarean section for preventing postoperative infections
Comparison: 3 Vaginal preparation versus control - stratified by presence of ruptured membranes
Outcome: 2 Postoperative fever
Study or subgroup Vaginal cleansing Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Women with ruptured membranes
Haas 2010 1/34 4/42 52.5 % 0.31 [ 0.04, 2.64 ]
Subtotal (95% CI) 34 42 52.5 % 0.31 [ 0.04, 2.64 ]
Total events: 1 (Vaginal cleansing), 4 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.07 (P = 0.28)
2 Women with intact membranes
Haas 2010 1/121 3/103 47.5 % 0.28 [ 0.03, 2.69 ]
Subtotal (95% CI) 121 103 47.5 % 0.28 [ 0.03, 2.69 ]
Total events: 1 (Vaginal cleansing), 3 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.10 (P = 0.27)
Total (95% CI) 155 145 100.0 % 0.30 [ 0.06, 1.40 ]
Total events: 2 (Vaginal cleansing), 7 (Control)
Heterogeneity: Chi2 = 0.00, df = 1 (P = 0.96); I2 =0.0%
Test for overall effect: Z = 1.53 (P = 0.13)
Test for subgroup differences: Chi2 = 0.00, df = 1 (P = 0.96), I2 =0.0%
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Analysis 3.3. Comparison 3 Vaginal preparation versus control - stratified by presence of ruptured
membranes, Outcome 3 Wound infection.
Review: Vaginal preparation with antiseptic solution before cesarean section for preventing postoperative infections
Comparison: 3 Vaginal preparation versus control - stratified by presence of ruptured membranes
Outcome: 3 Wound infection
Study or subgroup Vaginal cleansing Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Women with ruptured membranes
Guzman 2002 6/36 1/36 7.2 % 6.00 [ 0.76, 47.36 ]
Haas 2010 2/34 5/42 32.2 % 0.49 [ 0.10, 2.39 ]
Subtotal (95% CI) 70 78 39.4 % 1.50 [ 0.52, 4.32 ]
Total events: 8 (Vaginal cleansing), 6 (Control)
Heterogeneity: Chi2 = 3.64, df = 1 (P = 0.06); I2 =72%
Test for overall effect: Z = 0.75 (P = 0.45)
2 Women with intact membranes
Guzman 2002 1/44 3/44 21.6 % 0.33 [ 0.04, 3.08 ]
Haas 2010 5/121 5/103 38.9 % 0.85 [ 0.25, 2.86 ]
Subtotal (95% CI) 165 147 60.6 % 0.67 [ 0.23, 1.89 ]
Total events: 6 (Vaginal cleansing), 8 (Control)
Heterogeneity: Chi2 = 0.53, df = 1 (P = 0.47); I2 =0.0%
Test for overall effect: Z = 0.76 (P = 0.45)
Total (95% CI) 235 225 100.0 % 1.00 [ 0.48, 2.06 ]
Total events: 14 (Vaginal cleansing), 14 (Control)
Heterogeneity: Chi2 = 4.66, df = 3 (P = 0.20); I2 =36%
Test for overall effect: Z = 0.01 (P = 0.99)
Test for subgroup differences: Chi2 = 1.15, df = 1 (P = 0.28), I2 =13%
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Analysis 3.4. Comparison 3 Vaginal preparation versus control - stratified by presence of ruptured
membranes, Outcome 4 Any wound complication.
Review: Vaginal preparation with antiseptic solution before cesarean section for preventing postoperative infections
Comparison: 3 Vaginal preparation versus control - stratified by presence of ruptured membranes
Outcome: 4 Any wound complication
Study or subgroup Vaginal cleansing Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Women with ruptured membranes
Haas 2010 3/34 7/42 45.3 % 0.53 [ 0.15, 1.89 ]
Subtotal (95% CI) 34 42 45.3 % 0.53 [ 0.15, 1.89 ]
Total events: 3 (Vaginal cleansing), 7 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.98 (P = 0.33)
2 Women with intact membranes
Haas 2010 6/121 7/103 54.7 % 0.73 [ 0.25, 2.10 ]
Subtotal (95% CI) 121 103 54.7 % 0.73 [ 0.25, 2.10 ]
Total events: 6 (Vaginal cleansing), 7 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.58 (P = 0.56)
Total (95% CI) 155 145 100.0 % 0.64 [ 0.28, 1.44 ]
Total events: 9 (Vaginal cleansing), 14 (Control)
Heterogeneity: Chi2 = 0.14, df = 1 (P = 0.70); I2 =0.0%
Test for overall effect: Z = 1.08 (P = 0.28)
Test for subgroup differences: Chi2 = 0.14, df = 1 (P = 0.70), I2 =0.0%
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Analysis 3.5. Comparison 3 Vaginal preparation versus control - stratified by presence of ruptured
membranes, Outcome 5 Composite wound complication or endometritis.
Review: Vaginal preparation with antiseptic solution before cesarean section for preventing postoperative infections
Comparison: 3 Vaginal preparation versus control - stratified by presence of ruptured membranes
Outcome: 5 Composite wound complication or endometritis
Study or subgroup Vaginal cleansing Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Women with ruptured membranes
Haas 2010 3/34 8/42 42.4 % 0.46 [ 0.13, 1.61 ]
Subtotal (95% CI) 34 42 42.4 % 0.46 [ 0.13, 1.61 ]
Total events: 3 (Vaginal cleansing), 8 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.21 (P = 0.23)
2 Women with intact membranes
Haas 2010 7/121 9/103 57.6 % 0.66 [ 0.26, 1.72 ]
Subtotal (95% CI) 121 103 57.6 % 0.66 [ 0.26, 1.72 ]
Total events: 7 (Vaginal cleansing), 9 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.85 (P = 0.40)
Total (95% CI) 155 145 100.0 % 0.58 [ 0.27, 1.23 ]
Total events: 10 (Vaginal cleansing), 17 (Control)
Heterogeneity: Chi2 = 0.20, df = 1 (P = 0.66); I2 =0.0%
Test for overall effect: Z = 1.43 (P = 0.15)
Test for subgroup differences: Chi2 = 0.20, df = 1 (P = 0.66), I2 =0.0%
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A P P E N D I C E S
Appendix 1. Methods used to be used in future updates
Data collection and analysis
Selection of studies
At least two review authors will independently assess for inclusion all the potential studies we identify as a result of the search strategy.
We will resolve any disagreement through discussion or, if required, we will consult a third author.
We will create a study flow diagram to map out the number of records identified, included and excluded.
Data extraction and management
We will design a form to extract data. For eligible studies, at least two review authors will extract the data using the agreed form. We
will resolve discrepancies through discussion or, if required, we will consult a third author. We will enter data into Review Manager
software (RevMan 2014) and check for accuracy.
When information regarding any of the above is unclear, we will attempt to contact authors of the original reports to provide further
details.
Assessment of risk of bias in included studies
Two review authors will independently assess risk of bias for each study using the criteria outlined in the Cochrane Handbook for
Systematic Reviews of Interventions (Higgins 2011). We will resolve any disagreement by discussion or by involving a third assessor.
(1) Random sequence generation (checking for possible selection bias)
We will describe for each included study the method used to generate the allocation sequence in sufficient detail to allow an assessment
of whether it should produce comparable groups.
We will assess the method as:
• low risk of bias (any truly random process, e.g. random number table; computer random number generator);
• high risk of bias (any non-random process, e.g. odd or even date of birth; hospital or clinic record number);
• unclear risk of bias.
(2) Allocation concealment (checking for possible selection bias)
We will describe for each included study the method used to conceal allocation to interventions prior to assignment and will assess
whether intervention allocation could have been foreseen in advance of, or during recruitment, or changed after assignment.
We will assess the methods as:
• low risk of bias (e.g. telephone or central randomization; consecutively numbered sealed opaque envelopes);
• high risk of bias (open random allocation; unsealed or non-opaque envelopes, alternation; date of birth);
• unclear risk of bias.
(3.1) Blinding of participants and personnel (checking for possible performance bias)
We will describe for each included study the methods used, if any, to blind study participants and personnel from knowledge of which
intervention a participant received. We will consider that studies are at low risk of bias if they were blinded, or if we judge that the lack
of blinding would be unlikely to affect results. We will assess blinding separately for different outcomes or classes of outcomes.
We will assess the methods as:
• low, high or unclear risk of bias for participants;
• low, high or unclear risk of bias for personnel.
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(3.2) Blinding of outcome assessment (checking for possible detection bias)
We will describe for each included study the methods used, if any, to blind outcome assessors from knowledge of which intervention a
participant received. We will assess blinding separately for different outcomes or classes of outcomes.
We will assess methods used to blind outcome assessment as:
• low, high or unclear risk of bias.
(4) Incomplete outcome data (checking for possible attrition bias due to the amount, nature and handling of incomplete
outcome data)
We will describe for each included study, and for each outcome or class of outcomes, the completeness of data including attrition and
exclusions from the analysis. We will state whether attrition and exclusions were reported and the numbers included in the analysis at
each stage (compared with the total randomized participants), reasons for attrition or exclusion where reported, and whether missing
data were balanced across groups or were related to outcomes. Where sufficient information is reported, or can be supplied by the trial
authors, we will re-include missing data in the analyses which we undertake.
We will assess methods as:
• low risk of bias (e.g. no missing outcome data; missing outcome data balanced across groups);
• high risk of bias (e.g. numbers or reasons for missing data imbalanced across groups; ‘as treated’ analysis done with substantial
departure of intervention received from that assigned at randomization);
• unclear risk of bias.
(5) Selective reporting (checking for reporting bias)
We will describe for each included study how we investigated the possibility of selective outcome reporting bias and what we found.
We will assess the methods as:
• low risk of bias (where it is clear that all of the study’s pre-specified outcomes and all expected outcomes of interest to the review
have been reported);
• high risk of bias (where not all the study’s pre-specified outcomes have been reported; one or more reported primary outcomes
were not pre-specified; outcomes of interest are reported incompletely and so cannot be used; study fails to include results of a key
outcome that would have been expected to have been reported);
• unclear risk of bias.
(6) Other bias (checking for bias due to problems not covered by (1) to (5) above)
We will describe for each included study any important concerns we have about other possible sources of bias.
We will assess whether each study was free of other problems that could put it at risk of bias:
• low risk of other bias;
• high risk of other bias;
• unclear whether there is risk of other bias.
(7) Overall risk of bias
We will make explicit judgements about whether studies are at high risk of bias, according to the criteria given in the Handbook (
Higgins 2011). With reference to (1) to (6) above, we will assess the likely magnitude and direction of the bias and whether we consider
it is likely to impact on the findings. We will explore the impact of the level of bias through undertaking sensitivity analyses - see
Sensitivity analysis.
Measures of treatment effect
Dichotomous data
For dichotomous data, we will present results as summary risk ratio with 95% confidence intervals.
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Continuous data
For continuous data, we will use the mean difference if outcomes are measured in the same way between trials. We will use the
standardized mean difference to combine trials that measure the same outcome, but use different methods.
Unit of analysis issues
Cluster-randomized trials
We will include cluster-randomized trials in the analyses along with individually-randomized trials. We will adjust their sample sizes
using the methods described in the Handbook [Section 16.3.4 or 16.3.6] using an estimate of the intracluster correlation co-efficient
(ICC) derived from the trial (if possible), from a similar trial or from a study of a similar population. If we use ICCs from other
sources, we will report this and conduct sensitivity analyses to investigate the effect of variation in the ICC. If we identify both cluster-
randomized trials and individually-randomized trials, we plan to synthesize the relevant information. We will consider it reasonable
to combine the results from both if there is little heterogeneity between the study designs and the interaction between the effect of
intervention and the choice of randomization unit is considered to be unlikely.
We will also acknowledge heterogeneity in the randomization unit and perform a sensitivity analysis to investigate the effects of the
randomization unit.
Cross-over trials
We determined that it was not possible to include cross-over trials in this review.
Other unit of analysis issues
Dealing with missing data
For included studies, we will note levels of attrition. We will explore the impact of including studies with high levels of missing data in
the overall assessment of treatment effect by using sensitivity analysis.
For all outcomes, we will carry out analyses, as far as possible, on an intention-to-treat basis, i.e. we will attempt to include all participants
randomized to each group in the analyses, and all participants will be analyzed in the group to which they were allocated, regardless of
whether or not they received the allocated intervention. The denominator for each outcome in each trial will be the number randomized
minus any participants whose outcomes are known to be missing.
Assessment of heterogeneity
We will assess statistical heterogeneity in each meta-analysis using the Tau², I² and Chi² statistics. We will regard heterogeneity as
substantial if an I² is greater than 30% and either a Tau² is greater than zero, or there is a low P value (less than 0.10) in the Chi² test
for heterogeneity.
Assessment of reporting biases
If there are 10 or more studies in the meta-analysis, we will investigate reporting biases (such as publication bias) using funnel plots.
We will assess funnel plot asymmetry visually. If asymmetry is suggested by a visual assessment, we will perform exploratory analyses
to investigate it.
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Data synthesis
We will carry out statistical analysis using the Review Manager software (RevMan 2014). We will use fixed-effect meta-analysis for
combining data where it is reasonable to assume that studies are estimating the same underlying treatment effect: i.e. where trials are
examining the same intervention, and the trials’ populations and methods are judged sufficiently similar. If there is clinical heterogeneity
sufficient to expect that the underlying treatment effects differ between trials, or if substantial statistical heterogeneity is detected, we
will use random-effects meta-analysis to produce an overall summary, if an average treatment effect across trials is considered clinically
meaningful. The random-effects summary will be treated as the average of the range of possible treatment effects and we will discuss
the clinical implications of treatment effects differing between trials. If the average treatment effect is not clinically meaningful, we will
not combine trials.
If we use random-effects analyses, the results will be presented as the average treatment effect with 95% confidence intervals, and the
estimates of Tau² and I².
Subgroup analysis and investigation of heterogeneity
We plan to carry out the following subgroup analyses for primary outcomes:
1. cesarean after labor versus cesarean with no preceding labor;
2. ruptured membranes versus intact membranes;
3. chorioamnionitis versus no chorioamnionitis;
4. emergency versus unscheduled versus scheduled cesarean delivery;
5. intrapartum internal monitoring devices versus no internal monitoring devices.
We will assess subgroup differences by interaction tests available within RevMan (RevMan 2014).We will report the results of subgroup
analyses quoting the Chi² statistic and P value, and the interaction test I² value.
Sensitivity analysis
We plan to perform sensitivity analyses to explore the effect of study quality relating to the ’Risk of bias’ items including allocation
concealment, incomplete data collection to assess for any substantive difference to the overall result. If cluster-randomized trials are
included in the review, we aim to apply other sensitivity analysis incorporating an estimate of the ICC taken from a different study, to
see what the effect of different values of the ICC on the results of the analysis would be.
WH A T ’ S N E W
Last assessed as up-to-date: 21 July 2014.
Date Event Description
21 July 2014 New search has been performed Search updated. No new trial reports identified.
21 July 2014 New citation required but conclusions have not changed Review updated.
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H I S T O R Y
Protocol first published: Issue 3, 2009
Review first published: Issue 3, 2010
Date Event Description
14 September 2012 New citation required but conclusions have not
changed
Review updated.
14 September 2012 New search has been performed Search updated. One new trial included (Asghania
2011) and the published report of Haas 2010 added.
C O N T R I B U T I O N S O F A U T H O R S
All review authors helped develop the protocol, data extraction, and preparation of results and final report.
D E C L A R A T I O N S O F I N T E R E S T
There are no financial conflicts of interest to disclose. David Haas is the Principal Investigator for a randomized trial included in this
review (Haas 2010). Sarah Morgan is also an investigator in the same trial. Trial authors were not involved in assessing trial quality or
extracting data from the Haas 2010 study, this was carried out by the third review author, Karenrose Contreras and a third party (Dr
Jon Hathaway, MD, PhD).
S O U R C E S O F S U P P O R T
Internal sources
• Indiana University School of Medicine, Indianapolis, USA.
External sources
• UNDP-UNFPA-UNICEF-WHO-World Bank Special Programme of Research, Development and Research Training in Human
Reproduction (HRP), Department of Reproductive Health and Research (RHR), World Health Organization, Switzerland.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
Three of the planned subgroup analyses were unable to be performed as they were not reported in the trials.
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I N D E X T E R M S
Medical Subject Headings (MeSH)
Administration, Intravaginal; Anti-Infective Agents, Local [∗administration &dosage]; Cesarean Section [∗adverse effects]; Disinfection
[∗methods]; Endometritis [∗prevention & control]; Povidone-Iodine [∗administration & dosage]; Randomized Controlled Trials as
Topic; Surgical Wound Infection [∗prevention & control]; Vagina
MeSH check words
Female; Humans; Pregnancy
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